Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-021-00219-7, published online 8 February 2021
The original version of the published Article had an error in the Author affiliations. The second affiliation for co-Author Michal Marczyk was inadvertently omitted. The following affiliation has been added: Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland. The HTML and PDF versions of the Article have been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Foldi, J., Silber, A., Reisenbichler, E. et al. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. npj Breast Cancer 8, 17 (2022). https://doi.org/10.1038/s41523-022-00392-3
Published:
DOI: https://doi.org/10.1038/s41523-022-00392-3
